Phage Lytic Protein CHAPSH3b Encapsulated in Niosomes and Gelatine Films
- PMID: 38257944
- PMCID: PMC10819965
- DOI: 10.3390/microorganisms12010119
Phage Lytic Protein CHAPSH3b Encapsulated in Niosomes and Gelatine Films
Abstract
Antimicrobial resistance (AMR) has emerged as a global health challenge, sparking worldwide interest in exploring the antimicrobial potential of natural compounds as an alternative to conventional antibiotics. In recent years, one area of focus has been the utilization of bacteriophages and their derivative proteins. Specifically, phage lytic proteins, or endolysins, are specialized enzymes that induce bacterial cell lysis and can be efficiently produced and purified following overexpression in bacteria. Nonetheless, a significant limitation of these proteins is their vulnerability to certain environmental conditions, which may impair their effectiveness. Encapsulating endolysins in vesicles could mitigate this issue by providing added protection to the proteins, enabling controlled release, and enhancing their stability, particularly at temperatures around 4 °C. In this work, the chimeric lytic protein CHAPSH3b was encapsulated within non-ionic surfactant-based vesicles (niosomes) created using the thin film hydrating method (TFH). These protein-loaded niosomes were then characterized, revealing sizes in the range of 30-80 nm, zeta potentials between 30 and 50 mV, and an encapsulation efficiency (EE) of 50-60%. Additionally, with the objective of exploring their potential application in the food industry, these endolysin-loaded niosomes were incorporated into gelatine films. This was carried out to evaluate their stability and antimicrobial efficacy against Staphylococcus aureus.
Keywords: antimicrobial activity; encapsulation; endolysin; gelatine films; niosomes.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
References
-
- WHO . Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis. WHO; Geneva, Switzerland: 2017.
-
- European Centre for Disease Prevention and Control . Antimicrobial Resistance Surveillance in Europe. European Centre for Disease Prevention and Control; Solna, Sweden: 2022.
Grants and funding
LinkOut - more resources
Full Text Sources
